What is Candel Therapeutics, Inc.'s net investment in lease?

Candel Therapeutics, Inc. (CADL) reported net investment in lease of $1.57M in Q1 2026.

How has Candel Therapeutics, Inc.'s net investment in lease changed year-over-year?

Candel Therapeutics, Inc.'s net investment in lease increased by 235.3% year-over-year, from $468K to $1.57M.

What is the long-term trend for Candel Therapeutics, Inc.'s net investment in lease?

Over 3 years (2022 to 2025), Candel Therapeutics, Inc.'s net investment in lease has grown at a 16.3% compound annual growth rate (CAGR), from $1.06M to $1.66M.

Candel Therapeutics, Inc. CADL Net Investment in Lease

Net Investment in Lease at other companies

Replimune GroupREPL

——

CG OncologyCGON

——

Immix Biopharma, Inc.IMMX

——

CytomX TherapeuticsCTMX

——

RegenxbioRGNX

——

ImmunomeIMNM

——

Other financials

Income statement

See full

Revenue$31.0K0.0%

Operating income-$16.3M-100%

Net income-$8.9M-220%

EPS (diluted)-$0.14-208%

Balance sheet

See full

Cash & equivalents$194.8M+111%

Total debt$2.8M-73.9%

Total equity$138.0M+84.8%

Total assets$201.9M+111%

Cash flow

See full

Operating cash flow-$18.0M-109%

CapEx$675.0K+22,400%

Free cash flow-$18.7M-117%

Valuation

See full

Market cap$693.87M+192%

Enterprise value$501.88M+220%

P/S5,595.7×-18,674×

Profitability

See full

Operating margin-28,000.8%+15,050pp

Net margin-15,156.5%-5,064pp

FCF margin-26,383.9%+14,851pp

Returns & leverage

See full

Return on equity-51.2%-16.6pp

Debt / equity0×-0.1×

Current ratio28×+23.4×

Where this comes from

Reported directly by Candel Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Candel Therapeutics, Inc.'s net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Candel Therapeutics, Inc.'s net investment in lease?: Candel Therapeutics, Inc. (CADL) reported net investment in lease of $1.57M in Q1 2026.
How has Candel Therapeutics, Inc.'s net investment in lease changed year-over-year?: Candel Therapeutics, Inc.'s net investment in lease increased by 235.3% year-over-year, from $468K to $1.57M.
What is the long-term trend for Candel Therapeutics, Inc.'s net investment in lease?: Over 3 years (2022 to 2025), Candel Therapeutics, Inc.'s net investment in lease has grown at a 16.3% compound annual growth rate (CAGR), from $1.06M to $1.66M.